Sign In
Buy RANI
$0.88
+0.0174 (+2.03%)
At Close: Jun 03, 2026
SAN JOSE, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral
Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition
04:05pm, Friday, 15'th May 2026
- Continued advancement of the ongoing Phase 1 study of RT-114 via RaniPill® for the treatment of obesity in collaboration with ProGen –
Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference
04:05pm, Tuesday, 12'th May 2026
SAN JOSE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral
Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy
07:00am, Thursday, 09'th Apr 2026
SAN JOSE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the or
Rani Therapeutics Holdings, Inc. (RANI) Q4 2025 Earnings Call Transcript
08:15pm, Thursday, 26'th Mar 2026
Rani Therapeutics Holdings, Inc. (RANI) Q4 2025 Earnings Call Transcript
Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update
04:05pm, Thursday, 26'th Mar 2026
- Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics and completed $60.3 million oversubscribed private placement led by Samsara BioCapita
Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization
04:53pm, Wednesday, 25'th Mar 2026
SAN JOSE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the or
Milestone Pharmaceuticals (NASDAQ:MIST) versus Rani Therapeutics (NASDAQ:RANI) Head to Head Review
01:32am, Friday, 20'th Mar 2026
Rani Therapeutics (NASDAQ: RANI - Get Free Report) and Milestone Pharmaceuticals (NASDAQ: MIST - Get Free Report) are both small-cap medical companies, but which is the superior business? We will comp
Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results
04:05pm, Thursday, 19'th Mar 2026
SAN JOSE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the or
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Average Recommendation of “Moderate Buy” from Brokerages
03:12am, Sunday, 22'nd Feb 2026
Rani Therapeutics Holdings, Inc. (NASDAQ: RANI - Get Free Report) has earned an average recommendation of "Moderate Buy" from the five analysts that are presently covering the stock, MarketBeat Rating
Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer
07:00am, Wednesday, 28'th Jan 2026
SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the ora
Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen
07:00am, Thursday, 08'th Jan 2026
- A phase 1 study to evaluate safety, tolerability, bioavailability, pharmacokinetics, and weight loss of GLP-1/GLP-2 dual agonist, PG-102, administered orally via RaniPill® capsule versus subcutaneo
Rani Therapeutics (NASDAQ:RANI) Stock Price Down 2.2% – What’s Next?
01:32am, Wednesday, 31'st Dec 2025
Rani Therapeutics Holdings, Inc. (NASDAQ: RANI - Get Free Report)'s share price fell 2.2% during mid-day trading on Tuesday. The stock traded as low as $1.35 and last traded at $1.35. 1,356,778 shares
Rani Therapeutics to Participate in the Evercore Healthcare Conference
04:05pm, Monday, 24'th Nov 2025
SAN JOSE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the ora
Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update
04:30pm, Thursday, 06'th Nov 2025
– Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics –
